GoAI
Get started
Niki BioSolutions, Inc. logo

Niki BioSolutions, Inc.

NIKI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$8.58

+$0.38 · +4.63%

Aug 21, 4:00 PM ET

NIKI company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Chung Yuen Huen
Listed since
Jul 20, 2026
Employees
1

Market position

Day range

Current $8.58

52-week range

Current $8.58

Open
$8.31
Previous close
$8.20
Volume
30.46K
0.39× average
Average volume
78.86K
Average daily volume
Market cap
698.73K USD
Beta
0.17
Market reference 1
50-day average
$8.4694
+1.31% above average
200-day average
$9.6818
-11.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
7.78M USD
P/E (TTM)
-0.45×
P/B (TTM)
0.03×
P/S (TTM)
0×
EV / EBITDA
-4.28×
Earnings yield
-17.49%
Free cash flow yield
-23.57%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-5.89%
Return on assets
-7.29%
Return on invested capital
-10.36%

Financial health

Debt / equity
0.15×
Current ratio
0.78×
Altman Z-score
-5.78
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends253%-733%-1718%-2704%Gross margin, FY2021: 5.31%Gross margin, FY2022: 6.18%Gross margin, FY2023: 2.45%Operating margin, FY2021: -1245.59%Operating margin, FY2022: -1351.01%Operating margin, FY2023: -2457.47%Net margin, FY2021: -1624.38%Net margin, FY2022: -756.17%Net margin, FY2023: -654.88%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 5.31%. Gross margin FY2022 6.18%. Gross margin FY2023 2.45%. Operating margin FY2021 -1245.59%. Operating margin FY2022 -1351.01%. Operating margin FY2023 -2457.47%. Net margin FY2021 -1624.38%. Net margin FY2022 -756.17%. Net margin FY2023 -654.88%.

Income trends

Revenue

431.38K USD-66.71%

Operating income

−1.82M USD+52.12%

Net income

−1.36M USD+68.06%
Income trends across reported periods4.2M USD−6.44M USD−17.07M USD−27.71M USDRevenue, FY2021: 1.54M USDRevenue, FY2022: 1.3M USDRevenue, FY2023: 431.38K USDOperating income, FY2021: −19.21M USDOperating income, FY2022: −17.51M USDOperating income, FY2023: −10.6M USDOperating income, FY2024: −3.8M USDOperating income, FY2025: −1.82M USDNet income, FY2021: −25.05M USDNet income, FY2022: −9.8M USDNet income, FY2023: −2.83M USDNet income, FY2024: −4.27M USDNet income, FY2025: −1.36M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.54M USD. Revenue FY2022 1.3M USD. Revenue FY2023 431.38K USD. Operating income FY2021 −19.21M USD. Operating income FY2022 −17.51M USD. Operating income FY2023 −10.6M USD. Operating income FY2024 −3.8M USD. Operating income FY2025 −1.82M USD. Net income FY2021 −25.05M USD. Net income FY2022 −9.8M USD. Net income FY2023 −2.83M USD. Net income FY2024 −4.27M USD. Net income FY2025 −1.36M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——431.38K USD1.3M USD1.54M USD
Cost of goods sold—255.05K USD420.81K USD1.22M USD1.46M USD
Gross profit—−255K USD10.57K USD80.07K USD81.85K USD
Research and development352.88K USD1.94M USD5.2M USD9.22M USD10.87M USD
Selling, general, and administrative1.64M USD1.47M USD4.42M USD7.97M USD8.03M USD
Operating expenses1.82M USD3.54M USD10.61M USD17.25M USD19.29M USD
Interest income———146.59K USD—
Interest expense95.71K USD146.92K USD121.15K USD—93.6K USD
Depreciation and amortization—255.05K USD1.13M USD1.21M USD1.19M USD
Operating income−1.82M USD−3.8M USD−10.6M USD−17.51M USD−19.21M USD
Net income−1.36M USD−4.27M USD−2.83M USD−9.8M USD−25.05M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.62

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates45.8712.66-20.56-53.77Q2 '19Q3 '19Q3 '20Q2 '21Q3 '21Q3 '22Q4 '25
Q2 2019, reported Apr 15, 2019: actual -0.531, estimate —, surprise —, Comparison unavailable. Q3 2019, reported Sep 26, 2019: actual -31.4, estimate —, surprise —, Comparison unavailable. Q3 2020, reported Sep 2, 2020: actual -20.7, estimate —, surprise —, Comparison unavailable. Q2 2021, reported Apr 19, 2021: actual 39, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 15, 2021: actual -46.9, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Sep 30, 2022: actual -5.3, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 8, 2025: actual -0.62, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates669.62K515.73K361.84K207.95KQ2 '19Q3 '19Q3 '20Q2 '21Q3 '21Q3 '22
Q2 2019, reported Apr 15, 2019: actual 383.45K USD, estimate —, surprise —, Comparison unavailable. Q3 2019, reported Sep 26, 2019: actual 239.79K USD, estimate —, surprise —, Comparison unavailable. Q3 2020, reported Sep 2, 2020: actual 327.27K USD, estimate —, surprise —, Comparison unavailable. Q2 2021, reported Apr 19, 2021: actual 584.24K USD, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 15, 2021: actual 637.78K USD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Sep 30, 2022: actual 527.46K USD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jul 20, 2026

1:10

NIKI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NIKI

research.disclaimer